T Cell Virus Protection

Unlocking T cells for Long-term Immunity & Protection from Virus'

Some highly efficacious antibody-based vaccines exist. However, many others have failed to induce long-term efficacy and protection. Studies provide evidence that effective prophylactic vaccines against complex viruses such as Coronavirus, West Nile Virus, Zika Virus, Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV) and herpes viruses must elicit a strong T cell immunity response. This has boosted research in this area but has not resulted in many vaccines capable of inducing sterilizing immunity.

Optimal virus clearance requires the induction of virus-specific T cells to promote long-term immunity.  Myeloid cells play an essential role in initiating and shaping virus-specific responses by presenting viral antigens to T cells for activation of the adaptive immune system. Conventional vaccines, however, do not optimally enable viral antigen transfer to dendritic cells and therefore do not result in a robust virus specific T cell response. Technology, originally developed in the laboratory of Michael Dee Gunn at Duke, has shown the potent ability of Myeloid cells to serve as the bridge to activate potent T cell responses. 

Myeloid Therapeutics in partnership with Duke University are developing the COVID-19 myeloid cell vaccine.

DUKE UNIVERSITY RESEARCH

© 2020,   Myeloid Therapeutics.  All rights reserved.

  • LinkedIn
  • Instagram
  • Twitter

GET IN

TOUCH

300 Technology Square, Suite 203  Cambridge, MA 02139